



CONGRESS 2024
SANTIAGO - CHILE 

SEPTEMBER 9th-11th

Scientific Program

PRELIMINARY

www.congresoaleh.com



ROOM A POSTGRADUATE COURSE Complications of liver cirrhosis MODERATORS Juanita Pérez, MD (MEXICO) - Gabriel Mezzano, MD (CHILE)		
09:00–11:00		
09:00–09:10	Welcome to the postgraduate course Graciela Castro, MD (MEXICO) • Javier Brahm, MD (CHILE)	
09:10–09:25	Current prevalence of chronic liver disease Jeffrey Lazarus, MD (SPAIN)	
09:25–09:40	New concepts on the stratification of compensated and decompensated cirrhosis according Baveno VII Guadalupe García-Tsao, MD (USA)	
09:40–09:55	Hepatic encephalopathy: old and new approaches Grace L. Su, MD (USA) 	
09:55–10:10	Treatment of acute kidney injury-Hepatorenal Syndrome Aldo Torre, MD (MEXICO)	
10:10–10:25	Refractory ascites: TIPS vs medical treatment Virginia Hernández, MD (SPAIN)	
10:25–10:40	Treatment of bacterial infections in patients with cirrhosis Sebastián Marciano, MD (ARGENTINA)	
10:40–11:00	Q&A Juanita Pérez, MD (MEXICO) - Gabriel Mezzano, MD (CHILE)	
11:00–11:30	BREAK / COMMERCIAL EXPO INAUGURATION	
11:30–13:00	MODERATORS Marco Arrese, MD (CHILE) • José Antonio Velarde, MD (MEXICO)	
11:30–11:45	Antibiotic prophylaxis for spontaneous bacterial peritonitis: benefit or risk? Angelo Mattos, MD (BRAZIL)	
11:45–12:00	Sarcopenia and frailty: a predictor of poor prognosis in liver cirrhosis Carlos Benítez, MD (CHILE)	
12:00–12:15	Comprehensive management in ACLF Mario Reis, MD (BRAZIL)	
12:15–12:30	Endoscopic tools in the hands of the hepatologist: Endohepatology Iván López-Méndez, MD (MEXICO)	
12:30–13:00	Q&A Marco Arrese, MD (CHILE) • José Antonio Velarde, MD (MEXICO)	

13:00–14:00		ROOM A CELLPHARMA SYMPOSIUM Liver fibrosis: a dynamic reversible process	ROOM EUROPA MERZ SYMPOSIUM Role of L-Ornithine-L-Aspartate (LOLA) in Hepatic Encephalopathy. New evidence in the recent LATAM Consensus and beyond.
14:30–15:45		MODERADORES Dr. Fernando Bessone (ARGENTINA) • Dra. Eira Cerda (MÉXICO)	14:00–18:00 ROOM ANTARTICA Artificial Intelligence Workshop Juan Turnes, MD (SPAIN) • Manuel Mendizabal, MD (ARGENTINA)
14:30–14:45	Practical considerations in volume management in cirrhosis patients Elliot Tapper, MD (USA) ⓘ		
14:45–15:00	Transplant in ACLF, are there any contraindications? George Therapondos, MD (USA) ⓘ		
15:00–15:15	Downstanding in transplantation and post immunotherapy reconversion therapy concept Federico Piñero, MD (ARGENTINA)		
15:15–15:30	Palliative care in end-stage liver disease José Presa, MD (PORTUGAL)		
15:30–15:45	Q&A Fernando Bessone, MD (ARGENTINA) • Eira Cerda, MD (MEXICO)		
15:45–16:15		BREAK	
16:15–17:50		SALÓN A Joint Session ALEH-EASL: Steatotic Liver Disease (SLD) MODERATORS Mario Pessoa, MD (BRAZIL) • Graciela Castro, MD (MEXICO)	
16:15–16:30	Implementation of the new nomenclature Francesco P. Russo, MD (ITALY) ⓘ		
16:30–16:45	The role of alcohol in SLD Aleksander Krag, MD (DENMARK) ⓘ		
16:45–17:00	Targering the gut microbiome to treat SLD *Virtual Conference Debbie Shawcross, MD (ENGLAND) ⓘ		
17:00–17:15	Stetatotic Liver Disease, MASLD and risk of chronic kidney disease Marcelo Silva, MD (ARGENTINA)		
17:15–17:30	Q&A Mario Pessoa, MD (BRAZIL) • Graciela Castro, MD (MEXICO)		
17:30–17:50	Closing of the postgraduate course Congress Inauguration Graciela Castro, M.D. (MEXICO)		

07:00–08:30	ROOM ANTARTICA Research Workshop Sebastián Marciano, MD (ARGENTINA) • Angelo Mattos, MD (BRAZIL)	
08:30–10:00	ROOM A AASLD-ALEH-APASL-EASL GLOBAL LIVER FORUM TOPIC Hepatitis B MODERATORS Graciela Castro, MD (MEXICO) • Nelia Hernández, MD (URUGUAY)	09:00–15:50 ROOM EUROPA Young Investigators Workshop AASLD
08:30–08:45	Should we treat patients in the Immunetolerant phase? Mario Pessoa, MD (BRAZIL)	
08:45–09:00	Can we stop nucleotide analogues in HBeAg negative patients? Francesco P. Russo, MD (ITALY) 	
09:00–09:15	From Chronic Hepatitis B to Hepatocellular Carcinoma. Who are the main players? W. Ray Kim, MD (USA) 	
09:15–09:30	New treatments for Chronic Hepatitis B Lai Wei, MD (CHINA) 	
09:30–10:00	Q&A Graciela Castro, MD (MEXICO) • Nelia Hernández, MD (URUGUAY)	
10:00–11:00	BREAK / POSTERS	
11:00–12:30	ROOM A MASLD I MODERATORS Fátima Higuera, MD (MEXICO) • Lorena Castro, MD (CHILE)	ROOM B Liver damage related alcohol consumption I MODERATORS José Luis Pérez, MD (MEXICO) • Enrique Carrera, MD (ECUADOR)
11:00–11:15	MASLD and risk of Hepatocellular Carcinoma Claudia D. Oliveira, MD (BRAZIL)	Molecular basis of alcohol withdrawal and relapse in alcohol-related liver disease Juan Pablo Roblero, MD (CHILE)
11:15–11:25	ORAL COMMUNICATION + Questions (7+3)	ORAL COMMUNICATION + Questions (7+3)
11:25–11:35	ORAL COMMUNICATION + Questions (7+3)	ORAL COMMUNICATION + Questions (7+3)
11:35–11:50	When to think about MetALD? Elisa Pose, MD (SPAIN)	Actions in Latin America on liver damage related to alcohol consumption Luis Antonio Díaz, MD (CHILE)
11:50–12:00	ORAL COMMUNICATION + Questions (7+3)	ORAL COMMUNICATION + Questions (7+3)
12:00–12:10	ORAL COMMUNICATION + Questions (7+3)	ORAL COMMUNICATION + Questions (7+3)
12:10–12:30	Q&A Fátima Higuera, MD (MEXICO) • Lorena Castro, MD (CHILE)	Q&A José Luis Pérez, MD (MEXICO) • Enrique Carrera, MD (ECUADOR)
12:30–14:00	INTERCEPT SYMPOSIUM	

ROOM A Autoimmunes Liver Disease MODERATORS Norberto Chávez, MD (MEXICO) • Leyla Nazal, MD (CHILE)		ROOM B Hepatocellular Carcinoma MODERATORS Ezequiel Ridruejo, MD (ARGENTINA) • Claudia Oliveira, MD (BRAZIL)	
14:00–14:15	Combined therapies in Primary Biliary Cholangitis Alejandra Villamil, MD (ARGENTINA)	New clinical trials and outcomes in the systemic treatment of HCC Sebastián Mondaca, MD (CHILE)	
14:15–14:25	ORAL COMMUNICATION + Questions (7+3)	ORAL COMMUNICATION + Questions (7+3)	
14:25–14:40	Atypical Forms of Autoimmune Hepatitis Álvaro Urzúa, MD (CHILE)	What is the best biomarker for diagnosis, treatment and follow-up in Hepatocellular Carcinoma? Josefina Pagés, MD (ARGENTINA)	
14:40–14:50	ORAL COMMUNICATION + Questions (7+3)	ORAL COMMUNICATION + Questions (7+3)	
14:50–15:05	Standard treatment and treatment alternatives in autoimmune hepatitis Claudia Couto, MD (BRAZIL)	Synergizing therapies in hepatocellular carcinoma: immunotherapy and locoregional therapies Federico Piñero, MD (ARGENTINA)	
15:05–15:25	Q&A Norberto Chávez, MD (MEXICO) • Leyla Nazal, MD (CHILE)	Q&A Ezequiel Ridruejo, MD (ARGENTINA) • Claudia Oliveira, MD (BRAZIL)	
15:25–16:10 BREAK / POSTERS			
ROOM A MASLD II MODERATORS Iván López-Méndez, MD (MEXICO) • Mario Reis, MD (BRAZIL)		ROOM B Hot Topics in Hepatology MODERATORS Rosalba Moreno, MD (MEXICO) • Josefina Pages, MD (ARGENTINA)	
16:10–16:25	Genetics and epigenetics in MASLD Norberto Chávez, MD (MEXICO)	HILI in Latin America Fernando Bessone, MD (ARGENTINA)	
16:25–16:40	MASLD and Type 2 Diabetes: A risk relationship Marco Arrese, MD (CHILE)	Hepatitis C in 2024 Fernando Contreras, MD (DOMINICAN REPUBLIC)	
16:40–16:55	Cardiovascular risk in MASLD: How to prevent and treat? Mónica Acevedo, MD (CHILE)	Fulminant hepatitis, when to do transplant? Santiago Muñoz, MD (CHILE)	
16:55–17:10	Non-invasive markers for the diagnosis, treatment and follow-up in MASLD Adrián Gadano, MD (ARGENTINA)	Immune-mediated hepatitis due to immune checkpoint inhibitors Nelia Hernández, MD (URUGUAY)	
17:10–17:30	Q&A Iván López-Méndez, MD (MEXICO) • Mario Reis, MD (BRAZIL)	Q&A Rosalba Moreno, MD (MEXICO) • Josefina Pages, MD (ARGENTINA)	
17:30–18:00	Master Conference Presentation MODERATORS Mario Pessoa, MD (BRAZIL) • Graciela Castro, MD (MEXICO)		
	State-of-the-art Lecture Update on the Global Epidemiology of MASLD and MASH Zobair Younoussi, MD (USA) 		
18:00–19:15 ALEH Assembly			

09:00 - 15.50

Young Investigators Workshop ALEH-AASLD

09:00–09:10	Introduction W. Ray Kim, MD (USA) • Manuel Mendizabal, MD (ARGENTINA)	12:00–12:20	Using social media to promote your science and career Elliot Tapper, MD (USA)
SESSION 1 - Academic Journey		12:20–12:30	Q&A Panel
09:10–09:30	Pursuing an academic career: risk, rewards and milestones Guadalupe García-Tsao, MD (USA)	SESSION 3 - Publication for high impact	
09:30–09:50	Building resilience and preventing burnout for long term success Grace L. Su, MD (USA)	12:30–12:50	How to write a paper and get published Luis Antonio Díaz, MD (CHILE)
09:50–10:10	What makes a healthy mentorship Brian Lee, MD (USA)	12:50–13:10	What editors look for in papers Norberto Chávez-Tapia, MD (MEXICO)
10:10–10:30	How to be a good mentee Marcos Arrese, MD (CHILE)	13:10–14:10	Networking lunch
10:30–10:40	Q&A Panel	SESSION 4 - Poster Session	
10:40–11:00	BREAK	14:10–15:40	Group 1: Viral Hepatitis Elliot Tapper, MD (USA) • Manuel Mendizabal, MD (ARGENTINA)
SESSION 2 - Generating and disseminating data			Group 2: Cirrhosis Guadalupe García-Tsao, MD (USA) • Luis Antonio Díaz, MD (CHILE)
11:00–11:20	Conceiving the research questions Sebastián Marciano, MD (ARGENTINA)		Group 3: Fatty Liver Sebastián Marciano, MD (ARGENTINA) • Brian Lee, MD (USA)
11:20–11:40	Fundamentals of observational studies W. Ray Kim, MD (USA)		Group 4: HCC Grace L. Su, MD (USA) • Mario Pessoa, MD (BRAZIL)
11:40–12:00	How to give effective presentation Manuel Mendizabal, MD (ARGENTINA)	15:40–15:50	Closing

07:00–08:15	ROOM ANTARTICA Interest Groups Meeting	
08:30–10:15	ROOM A AASLD-ALEH SYMPOSIUM From liver cirrhosis to liver transplantation MODERATORS Guadalupe García-Tsao, MD (USA) Manuel Mendizabal, MD (ARGENTINA)	08:30–12:30 ROOM EUROPA Hepocus Workshop Diego Arufe, MD (ARGENTINA) • Edgar Santino, MD (MEXICO) José Antonio Velarde, MD (MEXICO)
08:30–08:45	Strategies and technologies for improving mortality prediction, organ allocation and outcomes in liver transplantation W. Ray Kim, MD (USA) ⓘ	
08:45–09:00	Challenges in liver transplantation in Latin America Rodrigo Zapata, MD (CHILE)	
09:00–09:15	Frailty and Liver Transplantation Elliot Tapper, MD (USA) ⓘ	
09:15–09:30	Post-liver transplant immunotolerance Juanita Pérez, MD (MEXICO)	
09:30–09:45	Diagnosing liver cirrhosis through artificial intelligence Grace L. Su, MD (USA) ⓘ	
09:45–10:15	Q&A Guadalupe García-Tsao, MD (USA) • Manuel Mendizabal, MD (ARGENTINA)	
10:15–11:15	POSTERS	
11:15–13:00	ROOM A Miscellaneous MODERATORS Alejandro Soza, MD (CHILE) • Nicolás Fernández, MD (MEXICO)	ROOM B Hepatology Challenges MODERATORS Carlos Benítez, MD (CHILE) • Juan Miguel Abdo, MD (MEXICO)
11:15–11:30	Living Donor Liver Transplantation: In the real world George Therapondos, MD (USA)	11:15-11:30 Uncommon causes of hepatic steatosis Francisco Barrera, MD (CHILE)
11:30–11:40	ORAL COMMUNICATION + Questions (7+3)	11:30-11:45 Is reversal of liver fibrosis currently possible? Daniel Cabrera, MD (CHILE)
11:40–11:50	ORAL COMMUNICATION + Questions (7+3)	11:45-12:00 Clinical trials in primary biliary cholangitis Alejandra Villamil, MD (ARGENTINA)
11:50–12:05	Benign liver tumors Santiago Muñoz, MD (CHILE)	
12:05–12:15	ORAL COMMUNICATION + Questions (7+3)	12:00-12:15 Perioperative managment of patients with advanced chronic liver disease José Antonio Velarde, MD (MEXICO)
12:15–12:25	ORAL COMMUNICATION + Questions (7+3)	12:15-12:30 Adrenal failure in cirrhosis Jorge Garavito, MD (PERU)
12:25–12:40	Noninvasive markers in alcohol liver disease Aleksander Krag, MD (DENMARK) ⓘ	12:30-12:45 Indications of antioxidants in liver diseases José Luis Pérez, MD (MEXICO)
12:40–13:00	Q&A Alejandro Soza, MD (CHILE) • Ezequiel Ridruejo, MD (ARGENTINA)	12:45-13:00 Q&A Carlos Benítez, MD (CHILE) • Juan Miguel Abdo, MD (MEXICO)

13:00–14:30	ROOM A GILEAD SYMPOSIUM Keep it simple to achieve viral hepatitis elimination in Latin-America	
14:30–15:45	ROOM A Rounds in Hepatology I MODERATORS Brian Lee, MD [USA] • Gabriel Mezzano, MD [CHILE]	ROOM B Rounds in Hepatology II MODERATORS Nicolás Fernández, MD [MEXICO] • Kriss del Rocío Rodríguez, MD [PERU]
14:30–14:50	Transplantation in severe acute hepatitis related to alcohol FOR: George Therapondos, MD [USA] AGAINST: Elisa Pose, MD [SPAIN]	Benefits of new MASLD nomenclature Adrián Gadano, MD [ARGENTINA]
		Challenges ahead in LATAM Luis Antonio Díaz, MD [CHILE]
14:50–15:10	Serum ammonium levels: useful biomarker in decompensated liver cirrhosis FOR: Edgar Santino, MD [MEXICO] AGAINST: Juan Turnes, MD [SPAIN]	Use of TIPS in portal thrombosis FOR: Virginia Hernández, MD [SPAIN] AGAINST: Guadalupe García-Tsao, MD [USA]
15:10–15:30	Lifelong immunosuppression in autoimmune hepatitis FOR: Lorena Castro, MD [CHILE] AGAINST: Eira Cerda, MD [MEXICO]	Other indications for the use of albumin in cirrhosis FOR: Angelo Mattos, MD [BRAZIL] AGAINST: Aldo Torre, MD [MEXICO]
15:30–15:45	Q&A Brian Lee, MD [USA] • Gabriel Mezzano, MD [CHILE]	Q&A Nicolás Fernández, MD [MEXICO] • Kriss del Rocío Rodríguez, MD [PERU]
15:45–16:15	BREAK	
16:15–19:00	MODERATORS Manuel Mendizabal, MD [ARGENTINA] • Fernando Contreras, MD [DOMINICAN REPUBLIC]	
16:15– 16:35	Cultural Talk Javier Brahm, MD [CHILE]	
16:35– 16:55	Towards global recognition of the MASLD/MASH public health threat Jeffrey Lazarus, MD [ESPAÑA]	
16:55– 17:25	Round Table: Healthy Liver Healthy Lives COORDINATOR: JEFFREY LAZARUS, MD [SPAIN] Grace Su, MD [AASLD] • Aleksander Krag, MD [EASL] • Lai Wei, MD [APASL] • Mario Pessoa, MD [ALEH] • Zobair Younossi, MD [GNC]	
17:25–17:40	Oral Plenary 1	
17:40–17:55	Oral Plenary 2	
17:55–18:10	Oral Plenary 3	
18:10–18:20	Latin American Hepatologist Award	
18:20–18:30	International Hepatologist Award	
18:30–19:00	President's Report / Change of President	
19:00–19:30	CLOSURE	

 CONGRESS 2024
SANTIAGO - CHILE
SEPTEMBER 9th-11th

SPONSORS



echosens

CELL PHARMA



SISTER SOCIETIES



www.congresoaleh.com